We have located links that may give you full text access.
Case Reports
Journal Article
A Case of Type 2 Diabetes with a Change from a Non-Dipper to a Dipper Blood Pressure Pattern by Dapagliflozin.
Journal of UOEH 2016 June 2
Dapagliflozin, a selective inhibitor of sodium glucose co-transporter 2 (SGLT2), is a novel glucose-lowering agent that has pleiotropic actions on blood pressure and lipids. Its glucose-lowering effect is not mediated by insulin. We report a type 2 diabetic patient whose blood pressure pattern improved from non-dipper to dipper after treatment with dapagliflozin. The 60-year-old man was treated with 5 mg/day dapagliflozin, and the effect of treatment on his blood pressure (BP) was evaluated by ambulatory blood pressure monitoring (ABPM) before and at 8 and 14 days after the start of treatment. The 24-h systolic blood pressure/diastolic blood pressure decreased from 131/87 to 127/83 mmHg at day 14, with a particular decrease in nocturnal blood pressure from 123/84 to 116/75 mmHg (nocturnal blood pressure dip increased from 9.6% to 12.8%), changing from a non-dipper to a dipper blood pressure pattern. Dapagliflozin might potentially improve not only the average blood pressure, but also nighttime blood pressure from non-dipper to dipper in type 2 diabetic patients.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app